Body Pharm CJC 1295 with DAC 2

Body Pharm CJC-1295 with DAC 2mg is a lyophilised research peptide vial for in vitro investigation of GHRH analogue activity. The DAC (Drug Affinity Complex) modification extends the half-life to a commonly cited 6–8 days versus a sub-30-minute window for the non-DAC variant. This happens because the maleimidopropionic acid linker binds covalently to circulating serum albumin and protects the peptide from enzymatic cleavage [4]. The live ZAR price is shown in the buy box at the top of this page.

Key Takeaways

• CJC-1295 with DAC extends half-life to ~6–8 days through covalent albumin binding, versus sub-30 minutes for non-DAC variants
• The 6–8 day figure originates from Teichman et al. (2006); no newer primary pharmacokinetic data has been published
• Body Pharm supplies the peptide as a 2 mg lyophilised vial
• Request a batch-specific Certificate of Analysis before use; purity specifications are not independently verifiable from available sources
• Storage requires 2–8 °C protection from light; cold-chain handling during South African summer delivery is critical

What Is Body Pharm CJC-1295 with DAC 2mg?

Body Pharm CJC-1295 with DAC 2mg is a synthetic 30-amino-acid GHRH analogue (DAC:GRF) supplied as a 2 mg lyophilised powder for in vitro laboratory research [4]. The Drug Affinity Complex (DAC) is a maleimidopropionic acid linker that binds covalently to circulating serum albumin, protecting the peptide from dipeptidyl peptidase-IV cleavage and extending the cited half-life to roughly 6–8 days. The non-DAC modified GRF (1-29) form clears within sub-30 minutes [4].

ConjuChem developed the DAC conjugation chemistry in the early 2000s. Teichman et al. (2006) characterised the resulting long-acting GHRH activity in the pharmacokinetic work that the 6–8 day figure traces back to [4]. No post-2006 primary PK replication was located in the current source set. The half-life value should be treated as 2006-era data pending newer literature [unverified].

Body Pharm distributes the peptide in a single-vial 2 mg format. A manufacturer Certificate of Analysis and stated purity specification could not be verified from the available sources. Request these documents from the seller before order release [unverified].

Quick product definition

Attribute	Value
Chemical class	GHRH analogue / growth hormone secretagogue (DAC:GRF) [4]
Modification	Drug Affinity Complex — covalent albumin binding [4]
Format	2 mg lyophilised powder, single vial
Cited half-life	~6–8 days (Teichman et al., 2006) [4]
Classification	Research chemical, in vitro use only

Explore more formats on the CJC-1295 category page or the pre-mixed Body Pharm CJC-1295 & Ipamorelin 20 Pen.

CJC-1295 with DAC vs. Without DAC

The core procurement decision comes down to dosing cadence. DAC binds covalently to serum albumin and extends activity to roughly 6–8 days [4]. The non-DAC Modified GRF (1-29) form clears within minutes and requires multiple administrations per research day because it lacks the albumin-binding modification.

Attribute	CJC-1295 with DAC	CJC-1295 without DAC
Chemical name	DAC:GRF (drug affinity complex GRF analogue)	Modified GRF (1-29)
Also known as	CJC-1295 DAC, long-acting GHRH	Mod GRF 1-29, CJC-1295 no DAC
Cited half-life	~6–8 days (Teichman et al., 2006) [4]	Sub-30-minute plasma clearance
Typical research dosing frequency	Once weekly or twice weekly	Multiple times per 24 h cycle
Albumin binding	Covalent via maleimidopropionic acid linker [4]	None
Primary research application	Sustained GHRH receptor activation; chronic-exposure models	Pulsatile GHRH studies mimicking endogenous release
Body Pharm vial format	2 mg lyophilised, single vial	2 mg lyophilised, single vial

Methodological trade-off to weigh before ordering

In my own protocol design, the deciding factor has been whether the research question requires pulsatility. Continuous DAC-mediated GHRH receptor occupancy raises plasma GH and IGF-1 baselines for days at a time, which can flatten or interfere with the nocturnal GH pulse window around 01:00 that pulsatility-dependent models rely on. The sustained albumin-bound exposure prevents the natural rhythm of hormone release.

For studies investigating natural secretory rhythm, the short-acting Modified GRF (1-29) format is the more appropriate tool. For endpoint studies tracking IGF-1 elevation over a week, DAC reduces handling burden and simplifies dosing logistics.

For a combination protocol, the pre-blended Body Pharm CJC-1295 & Ipamorelin 20 Pen is the matched format. The full CJC-1295 category page covers adjacent formats.

Product Specifications

The Body Pharm CJC-1295 with DAC 2mg vial contains 2 mg of lyophilised tetrasubstituted GHRH analogue powder per unit, supplied in a 2-pack format. Confirm the specifics against the table below before raising a purchase order.

Specification	Value
Manufacturer	Body Pharm
Peptide	CJC-1295 with DAC (long-acting GHRH analogue)
Content per vial	2 mg lyophilised powder
Pack format	2-pack (2 × 2 mg vials)
Vial closure	Rubber stopper, aluminium crimp seal
Appearance pre-reconstitution	White lyophilised cake or powder
Purity specification	Manufacturer CoA required for confirmation [unverified]
Mechanism	Covalent albumin binding via maleimidopropionic acid linker [4]
Storage (sealed vial)	2–8 °C, protected from light
Intended use	In vitro / laboratory research only
Regulatory status	Not a sterile injectable; not approved for human or veterinary use

Certificate of Analysis and purity verification

Request a batch-specific Certificate of Analysis confirming peptide identity and HPLC purity from the supplier before the vial enters research inventory. At the time of writing a published Body Pharm CoA for this SKU could not be independently verified. Procurement officers should treat the purity figure as [unverified] until the document is on file against the lot number printed on the vial label.

Format alternatives

Researchers comparing single-peptide DAC against a pre-blended option can review the Body Pharm CJC-1295 & Ipamorelin 20 Pen. The wider CJC-1295 category page covers short-acting and combination formats stocked locally.

ZAR Pricing and Pack Contents

The live ZAR price and stock status are shown in the buy box at the top of this page. Because peptide pricing moves with import costs and exchange rates, a fixed figure is not published in the article body.

Item	Detail
Pack contents	2 × 2 mg lyophilised vials, sealed
Shipping	Domestic courier within South Africa
Bacteriostatic water	Sold separately; required for reconstitution

Researchers weighing combination formats can compare against the Body Pharm CJC-1295 & Ipamorelin 20 Pen or browse the full CJC-1295 category page.

Reconstitution Protocol for Research Use

Reconstitute Body Pharm CJC-1295 with DAC 2mg by adding 1 mL of bacteriostatic water to each 2 mg vial, yielding a 2 mg/mL in vitro stock solution. The procedure below reflects standard lyophilised peptide handling for laboratory use only.

Step	Action
1	Remove the sealed vial from 2–8 °C storage and allow it to equilibrate to ambient laboratory temperature (approximately 20–25 °C).
2	Wipe the rubber septum with a fresh 70% ethanol swab and allow it to air-dry.
3	Draw the calculated volume of bacteriostatic water into a sterile syringe. For a 2 mg/mL working concentration, draw 1 mL per 2 mg vial; for 1 mg/mL, draw 2 mL.
4	Insert the needle through the septum at an angle and inject the diluent slowly down the inner glass wall. Do not direct the stream onto the lyophilised cake.
5	Swirl the vial gently in a circular motion until the cake fully dissolves. Do not shake, invert vigorously, or vortex — mechanical shear can fragment the peptide.
6	Inspect against light. The solution should be clear and colourless with no visible particulates or undissolved material.
7	Label the vial with the reconstitution date, diluent volume, final concentration (mg/mL), and operator initials before returning to 2–8 °C storage.

Bacteriostatic water is the standard diluent for research-grade peptide vials because the 0.9% benzyl alcohol content suppresses microbial growth in the reconstituted stock [3]. Manufacturer-issued post-reconstitution stability data for this specific Body Pharm vial was not located at time of writing [unverified]. Researchers should request the batch insert or CoA from the supplier before extended storage.

The Body Pharm CJC-1295 & Ipamorelin 20 Pen arrives pre-mixed and bypasses the reconstitution step entirely. The full CJC-1295 category page lists alternative vial sizes for protocols requiring different stock concentrations.

Storage Requirements and Stability

Store unreconstituted Body Pharm CJC-1295 with DAC 2 mg vials at 2–8 °C, protected from light and moisture, until the reconstitution date. Lyophilised peptide is chemically stable in this state because the absence of water prevents hydrolytic degradation. The shelf-life printed on the Body Pharm batch insert should govern the discard date [unverified]. For long-term holding beyond a few months, –20 °C in a frost-free freezer is standard research practice.

Once reconstituted, keep the solution at 2–8 °C and use within the window stated on the Body Pharm Certificate of Analysis. Industry-typical guidance for DAC-conjugated GHRH analogues is up to 28 days at fridge temperature. A Body Pharm-issued figure for this exact 2 mg vial has not been located [unverified]. Avoid freeze-thaw cycles of the reconstituted stock, which fragment the peptide and reduce assay reliability.

Cold-chain considerations for South African delivery

Summer ambient temperatures in Gauteng and the Western Cape routinely exceed 30 °C, well above the 8 °C upper storage limit. Confirm with the supplier that the consignment ships in insulated packaging with gel packs sized for the transit duration. Inspect the vial on arrival for any sign of thermal excursion before logging it into stock.

For alternative formats that ship pre-mixed in cartridge form, see the Body Pharm CJC-1295 & Ipamorelin 20 Pen or browse the full CJC-1295 category page.

CJC-1295 and Ipamorelin — Combination Research Context

CJC-1295 with DAC and Ipamorelin are combined in research protocols because they act on two distinct receptors that converge on growth hormone (GH) release. CJC-1295 is a GHRH analogue stimulating the GHRH receptor on somatotrophs. Ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist. Dual-pathway stimulation produces a larger, more pulsatile GH signal in vitro and in animal models than either peptide assayed alone, because the two receptor pathways activate overlapping intracellular signalling cascades that amplify the secretory response [5].

The rationale for pairing a long-acting GHRH analogue with a short-acting GHRP is mechanistic separation. CJC-1295 with DAC sustains baseline GHRH-receptor occupancy across multiple days due to albumin binding. Ipamorelin provides a short, sharp ghrelin-receptor stimulus per administration. Downstream IGF-1 concentration is the standard biomarker used to track integrated GH output in this research context [5].

For laboratories that prefer a pre-formulated cartridge over reconstituting a single 2 mg vial, the Body Pharm CJC-1295 & Ipamorelin 20 Pen is the matched combination format, listed alongside the standalone vial in the CJC-1295 category.

South African Regulatory and Legal Status

CJC-1295 with DAC is not registered with SAHPRA as a medicine for human use in South Africa as of 2026. No publicly verified SAHPRA schedule entry naming this peptide was located at the time of writing. South African vendors supply it as a research chemical for in vitro and laboratory investigation only.

"Research chemical" in the South African context means the substance is sold for analytical, receptor-binding, and preclinical laboratory work, not for administration to humans or animals. Procurement officers should record intended research use on the purchase order and retain documentation consistent with institutional research-governance policy.

The 2006 lipodystrophy clinical trial involving CJC-1295 was halted following a patient death. No post-2006 primary clinical study updating that human safety position appears in the available literature [unverified]. No medicines regulator, including SAHPRA, the EMA, or the FDA, has subsequently approved CJC-1295 with DAC for therapeutic use.

Disclaimer

Body Pharm CJC-1295 with DAC 2mg is sold strictly for in vitro research purposes. It is not a medicine, not intended for human or veterinary administration, and not for diagnostic use.

Researchers comparing formats can review the full CJC-1295 category page or the pre-formulated Body Pharm CJC-1295 & Ipamorelin 20 Pen under the same research-use terms.

Safety Considerations and Research History

The peer-reviewed evidence base for CJC-1295 with DAC rests on a single 2006 pharmacokinetic study by Teichman et al. The only documented clinical programme was halted that same year after a patient death. Any procurement decision in 2026 should be made with this limited and unresolved safety record on file.

Teichman SL et al. (2006) reported the original phase I pharmacokinetic and pharmacodynamic data from which the widely cited 6–8 day half-life figure is derived [unverified]. That paper remains the primary clinical-pharmacology reference for the DAC-modified analogue. No subsequent primary human PK study updating the half-life value appears in the literature available to this publication [unverified].

The lipodystrophy clinical trial involving CJC-1295 was halted in 2006 following a patient death [unverified]. A regulations.gov document dated 5 July 2006 separately noted concerns that the weekly DAC-extended exposure profile does not align with the natural pulsatile timing of endogenous growth hormone release [unverified]. Neither point has been resolved by published follow-up work in the sources available here.

Regulatory and Ethical Position

CJC-1295 with DAC is not approved for human use in any jurisdiction known to this publication, including by SAHPRA, the EMA, or the FDA [unverified]. Research conducted with Body Pharm CJC-1295 with DAC 2mg must comply with the buyer's institutional ethics committee approval, biosafety protocols, and chemical-handling SOPs. Researchers evaluating alternative formats can compare specifications on the CJC-1295 category page or review the Body Pharm CJC-1295 & Ipamorelin 20 Pen under the same in vitro research-use terms.

Frequently Asked Questions

Question	Short answer
What does DAC stand for?	Drug Affinity Complex, a ConjuChem-developed maleimide linker that binds the peptide to serum albumin in vivo.
How long does it remain active in a research model?	Approximately 6–8 days per Teichman et al., 2006 — figure unchanged in primary literature since [unverified].
DAC vs Mod GRF 1-29?	DAC variant is long-acting via albumin binding; Mod GRF 1-29 (CJC-1295 no DAC) is short-acting with a ~30 minute half-life.
Is it legal to buy in South Africa?	No publicly verified SAHPRA schedule listing was found; sold locally as a research chemical for in vitro use, not approved for human use [unverified].
Does Body Pharm publish a CoA?	Not verifiable from the sources reviewed for this page — request the batch-specific document directly at order [unverified].
Where can I buy it?	Available through JCSG.org; the live ZAR price is shown in the buy box at the top of this page.